scispace - formally typeset
W

Wen Li

Researcher at Central South University Forestry and Technology

Publications -  10
Citations -  205

Wen Li is an academic researcher from Central South University Forestry and Technology. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 3, co-authored 3 publications receiving 13 citations.

Papers
More filters
Journal ArticleDOI

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

TL;DR: Wang et al. as mentioned in this paper reviewed the research progress and clinical application prospect of liquid biopsy technology for lung cancer and provided a review of the most common malignant tumors in China, including circulating tumor cells, exosomes, microRNA, circulating RNA, tumor platelets, and tumor endothelial cells.
Journal ArticleDOI

Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring

TL;DR: Wang et al. as mentioned in this paper reviewed the research progress and clinical application prospect of liquid biopsy technology for lung cancer and provided a review of the most common malignant tumors in China, including circulating tumor cells, exosomes, microRNA, circulating RNA, tumor platelets, and tumor endothelial cells.
Journal ArticleDOI

Targeting Colorectal Cancer Stem Cells as an Effective Treatment for Colorectal Cancer.

TL;DR: Targeting colorectal cancer stem cells, which are highly tumorigenic, aggressive, and chemoresistant and thus are critical in the metastasis and recurrence of coloreCTal cancer, may become an important research direction for the future cure of colors.
Journal ArticleDOI

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control:

TL;DR: Next-generation sequencing technology has developed rapidly and has become the core technology of precise targeted therapy and immunotherapy for cancer and plays an important role in optimizing treatment and evaluating the efficacy of different treatment options in clinical trials.